Neuland Laboratories has initiated a postal ballot process to seek shareholder approval for the appointment of Dr. Ravi Shankar Gopinath as an Independent Director. The company's Board of Directors, based on recommendations from the Nomination and Remuneration Committee, has proposed Dr. Gopinath's appointment for a five-year term.

Key Details of the Appointment

• Proposed Term: August 1, 2025, to July 31, 2030
• Position: Independent Director, not liable to retire by rotation
• Approval Process: Special Resolution through remote e-voting

About Dr. Ravi Shankar Gopinath

Dr. Gopinath, 59, brings a wealth of experience to Neuland Laboratories:

• Educational Background: Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute, New York; Masters in Chemical Engineering from IIT, Bombay
• Professional Experience:
  • Started career as a research scientist at Tata Consultancy Services (TCS)
  • Served as MD and CEO of Geometric Ltd.
  • Held leadership roles at AVEVA plc, including COO, CPO, and CSO
  • Executive positions at Schneider Electric Software and Invensys Software

Expertise and Competencies

Dr. Gopinath's areas of expertise include:

• Strategy formulation and execution
• Application of digital technologies
• Driving operational excellence
• M&A transactions and integration
• Organization change and leadership development

E-Voting Details

Board's Recommendation

The Board of Directors recommends the appointment of Dr. Ravi Shankar Gopinath, citing his rich experience and vast knowledge as a business leader. They believe his expertise aligns well with the company's needs and would be of immense benefit to Neuland Laboratories.

Shareholders are encouraged to participate in the e-voting process to cast their votes on this important appointment. The results of the postal ballot will be announced on or before September 28, 2025, at the company's registered office and will be communicated to the stock exchanges where Neuland Laboratories' securities are listed.

Neuland Laboratories , a leading pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), reported a significant decline in revenue for the first quarter. Despite the weak start, the company remains confident about its growth prospects for the full year.

Financial Performance

The company's total income for Q1 stood at Rs. 300.60 crores, marking a 32.4% decrease compared to Rs. 444.00 crores in the same period last year. The decline was primarily attributed to the uneven nature of order flows in their Contract Development and Manufacturing Organization (CDMO) and specialty Generic Drug Substances (GDS) business.

Key Financial Metrics

Business Segments Performance

The commercial CMS projects and the GDS Prime segment were the main contributors to revenue this quarter. The specialty GDS business was subdued, with only Dorzolamide contributing significantly.

Future Outlook

Despite the weak start, Neuland Laboratories remains optimistic about its growth prospects. The company expects:

1. Commercialization of another CMS molecule later this fiscal year
2. Commercial production from their Unit 3 facility
3. Growing customer interest in their peptide capabilities

Investments and Expansion

• CAPEX: Rs. 79.00 crores invested during the quarter
• Expected total CAPEX: Rs. 250.00 crores
• New peptide facility expected to be completed next financial year

Management Commentary

Saharsh Davuluri, Vice-Chairman and Managing Director, stated, "While the previous year was a year of consolidation and Q1 has been a continuation of that, our customer pipeline gives us good visibility. Hence, we are confident with the commercialization of Unit 3 production block. It will give the business greater revenue momentum from the latter half of the fiscal year."

Long-term Growth Target

The company reiterated its 3-5 year CAGR target of 20%, emphasizing its focus on balancing growth and profitability through continuous optimization of costs and processes.

In conclusion, while Neuland Laboratories faced a challenging first quarter, the management remains confident in the company's ability to achieve strong growth, driven by new product commercializations, capacity expansion, and growing interest in their peptide capabilities.